Journal article
Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma
Journal of pediatric hematology/oncology, Vol.39(7), pp.e370-e372
10/2017
DOI: 10.1097/MPH.0000000000000924
PMCID: PMC5772896
PMID: 28816792
Abstract
Ewing sarcoma is a pediatric bone and soft tissue sarcoma that requires intensive therapy, which can cause secondary malignancies. We present a rare case of early, treatment-related AML in a pediatric patient concurrently receiving primary therapy for Ewing sarcoma. Despite AML-directed therapy, our patient died secondary to complications of hyperleukocytosis. Cytogenetic and mutation profiling of the leukemia cells revealed the DNA-topoisomerase-II-inhibitor-associated t(9;11)(p22;q23) translocation and clonal KRAS and BRAF mutations. This report highlights the importance of monitoring for treatment-related effects in cancer therapy, as well as the need for novel, less toxic approaches in Ewing sarcoma therapy.
Details
- Title: Subtitle
- Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma
- Creators
- Brandon R McNew - University of Iowa Hospitals and Clinics, Iowa City, IA †Blank Children's Cancer and Blood Disorder Center, Des Moines, IABenjamin W DarbroDeqin MaDavid J Gordon
- Resource Type
- Journal article
- Publication Details
- Journal of pediatric hematology/oncology, Vol.39(7), pp.e370-e372
- DOI
- 10.1097/MPH.0000000000000924
- PMID
- 28816792
- PMCID
- PMC5772896
- NLM abbreviation
- J Pediatr Hematol Oncol
- ISSN
- 1077-4114
- eISSN
- 1536-3678
- Publisher
- United States
- Grant note
- P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 10/2017
- Academic Unit
- Stead Family Department of Pediatrics; Pathology; Medical Genetics and Genomics; Hematology/Oncology
- Record Identifier
- 9984047681802771
Metrics
23 Record Views